These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21845034)

  • 41. Pharmacologic management of diabetic peripheral neuropathic pain.
    Iyer S; Tanenberg RJ
    Expert Opin Pharmacother; 2013 Sep; 14(13):1765-75. PubMed ID: 23800105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain.
    Skljarevski V; Frakes EP; Sagman D; Lipsius S; Heinloth AN; Dueñas Tentori HJ
    Pain Res Treat; 2012; 2012():898347. PubMed ID: 22973509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study.
    Zhao Y; Liu J; Zhao Y; Thethi T; Fonseca V; Shi L
    Pain Pract; 2012 Jun; 12(5):366-73. PubMed ID: 21951753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does pain cause the perception of fatigue in patients with chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
    Fishbain DA; Hall JA; Risser RC; Gonzales JS
    Pain Pract; 2009; 9(5):354-62. PubMed ID: 19500272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
    Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
    Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysis.
    Crucitti A; Zhang Q; Nilsson M; Brecht S; Yang CR; Wernicke J
    Curr Med Res Opin; 2010 Nov; 26(11):2579-88. PubMed ID: 20874076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duloxetine for treating painful neuropathy or chronic pain.
    Lunn MP; Hughes RA; Wiffen PJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007115. PubMed ID: 19821395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of duloxetine in patients with chronic low back pain.
    Skljarevski V; Desaiah D; Liu-Seifert H; Zhang Q; Chappell AS; Detke MJ; Iyengar S; Atkinson JH; Backonja M
    Spine (Phila Pa 1976); 2010 Jun; 35(13):E578-85. PubMed ID: 20461028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China.
    Gao Y; Ning G; Jia WP; Zhou ZG; Xu ZR; Liu ZM; Liu C; Ma JH; Li Q; Cheng LL; Wen CY; Zhang SY; Zhang Q; Desaiah D; Skljarevski V
    Chin Med J (Engl); 2010 Nov; 123(22):3184-92. PubMed ID: 21163113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duloxetine for the management of fibromyalgia syndrome.
    Scholz BA; Hammonds CL; Boomershine CS
    J Pain Res; 2009 Jul; 2():99-108. PubMed ID: 21197298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.
    Armstrong DG; Chappell AS; Le TK; Kajdasz DK; Backonja M; D'Souza DN; Russell JM
    Pain Med; 2007; 8(5):410-8. PubMed ID: 17661854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.
    Barrett AM; Lucero MA; Le T; Robinson RL; Dworkin RH; Chappell AS
    Pain Med; 2007 Sep; 8 Suppl 2():S50-62. PubMed ID: 17714116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials.
    Sultan A; Gaskell H; Derry S; Moore RA
    BMC Neurol; 2008 Aug; 8():29. PubMed ID: 18673529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies.
    Kajdasz DK; Iyengar S; Desaiah D; Backonja MM; Farrar JT; Fishbain DA; Jensen TS; Rowbotham MC; Sang CN; Ziegler D; McQuay HJ
    Clin Ther; 2007; 29 Suppl():2536-46. PubMed ID: 18164920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee.
    Brown JP; Boulay LJ
    Ther Adv Musculoskelet Dis; 2013 Dec; 5(6):291-304. PubMed ID: 24294303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
    Wernicke JF; Wang F; Pritchett YL; Smith TR; Raskin J; D'Souza DN; Iyengar S; Chappell AS
    Pain Med; 2007 Sep; 8(6):503-13. PubMed ID: 17716324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy.
    Chen SY; Wu N; Boulanger L; Fraser KA; Zhao Y
    Pain Pract; 2010; 10(6):530-9. PubMed ID: 20412505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
    Fishbain DA; Hall J; Meyers AL; Gonzales J; Mallinckrodt C
    J Pain Symptom Manage; 2008 Dec; 36(6):639-47. PubMed ID: 18504092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
    Tanenberg RJ; Irving GA; Risser RC; Ahl J; Robinson MJ; Skljarevski V; Malcolm SK
    Mayo Clin Proc; 2011 Jul; 86(7):615-26. PubMed ID: 21719618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.